Literature DB >> 33642159

Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.

Jay A Spencer1, Tom Penfound2, Sanaz Salehi2, Michelle P Aranha3, Lauren E Wade2, Rupesh Agarwal3, Jeremy C Smith3, James B Dale2, Jerome Baudry4.   

Abstract

The M protein of group A streptococci (Strep A) is a major virulence determinant and protective antigen. The N-terminal sequence of the protein defines the more than 200 M types of Strep A and also contains epitopes that elicit opsonic antibodies, some of which cross-react with heterologous M types. Current efforts to develop broadly protective M protein-based vaccines are directed at identifying potential cross-protective epitopes located in the N-terminal regions of cluster-related M proteins for use as vaccine antigens. In this study, we have used a comprehensive approach using the recurrent neural network ABCpred and IEDB epitope conservancy analysis tools to predict 16 residue linear B-cell epitopes from 117 clinically relevant M types of Strep A (~88% of global Strep A infections). To examine the immunogenicity of these epitope-based vaccines, nine peptides that together shared ≥60% sequence identity with 37 heterologous M proteins were incorporated into two recombinant hybrid protein vaccines, in which the epitopes were repeated 2 or 3 times, respectively. The combined immune responses of immunized rabbits showed that the vaccines elicited significant levels of antibodies against all nine vaccine epitopes present in homologous N-terminal 1-50 amino acid synthetic M peptides, as well as cross-reactive antibodies against 16 of 37 heterologous M peptides predicted to contain similar epitopes. The epitope-specificity of the cross-reactive antibodies was confirmed by ELISA inhibition assays and functional opsonic activity was assayed in HL-60-based bactericidal assays. The results provide important information for the future design of broadly protective M protein-based Strep A vaccines.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioinformatics; Linear epitopes; M protein; Neural networks; Streptococcus pyogenes (S. pyogenes); Vaccine development

Year:  2021        PMID: 33642159      PMCID: PMC8045747          DOI: 10.1016/j.vaccine.2021.01.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Immunogenicity of a 26-valent group A streptococcal vaccine.

Authors:  Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.

Authors:  Thomas A Penfound; Edna Y Chiang; Elwaleed A Ahmed; James B Dale
Journal:  Vaccine       Date:  2010-05-21       Impact factor: 3.641

3.  Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015.

Authors:  David A Watkins; Catherine O Johnson; Samantha M Colquhoun; Ganesan Karthikeyan; Andrea Beaton; Gene Bukhman; Mohammed H Forouzanfar; Christopher T Longenecker; Bongani M Mayosi; George A Mensah; Bruno R Nascimento; Antonio L P Ribeiro; Craig A Sable; Andrew C Steer; Mohsen Naghavi; Ali H Mokdad; Christopher J L Murray; Theo Vos; Jonathan R Carapetis; Gregory A Roth
Journal:  N Engl J Med       Date:  2017-08-24       Impact factor: 91.245

4.  A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.

Authors:  Martina Sanderson-Smith; David M P De Oliveira; Julien Guglielmini; David J McMillan; Therese Vu; Jessica K Holien; Anna Henningham; Andrew C Steer; Debra E Bessen; James B Dale; Nigel Curtis; Bernard W Beall; Mark J Walker; Michael W Parker; Jonathan R Carapetis; Laurence Van Melderen; Kadaba S Sriprakash; Pierre R Smeesters
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

5.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.

Authors:  Shelly A McNeil; Scott A Halperin; Joanne M Langley; Bruce Smith; Andrew Warren; Geoffrey P Sharratt; Darlene M Baxendale; Mark A Reddish; Mary C Hu; Steven D Stroop; Janine Linden; Louis F Fries; Peter E Vink; James B Dale
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

Review 6.  Rapidly fatal necrotising fasciitis caused by Streptococcus pyogenes.

Authors:  P M Donaldson; B Naylor; J W Lowe; D R Gouldesbrough
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

7.  Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein.

Authors:  Cosmo Z Buffalo; Adrian J Bahn-Suh; Sophia P Hirakis; Tapan Biswas; Rommie E Amaro; Victor Nizet; Partho Ghosh
Journal:  Nat Microbiol       Date:  2016-09-05       Impact factor: 17.745

8.  Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence.

Authors:  Mattias C U Gustafsson; Jonas Lannergård; O Rickard Nilsson; Bodil M Kristensen; John E Olsen; Claire L Harris; Rafael L Ufret-Vincenty; Margaretha Stålhammar-Carlemalm; Gunnar Lindahl
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

9.  Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein.

Authors:  E H Beachey; G H Stollerman; R H Johnson; I Ofek; A L Bisno
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

10.  Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial.

Authors:  Silvana Sekuloski; Michael R Batzloff; Paul Griffin; William Parsonage; Suzanne Elliott; Jon Hartas; Peter O'Rourke; Louise Marquart; Manisha Pandey; Fran A Rubin; Jonathan Carapetis; James McCarthy; Michael F Good
Journal:  PLoS One       Date:  2018-07-02       Impact factor: 3.240

View more
  1 in total

1.  Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines.

Authors:  Michelle P Aranha; Thomas A Penfound; Sanaz Salehi; Anne Botteaux; Pierre Smeesters; James B Dale; Jeremy C Smith
Journal:  J Immunol       Date:  2021-08-02       Impact factor: 5.426

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.